Avirup Guha, Director of Cardio-Oncology at Medical College of Georgia, shared on X:
“A normal EF does not automatically mean low cardiac risk.
Following my ADT video, here’s the anthracycline companion: ESC 2022 risk assessment, plus newer CARDIOTOX, RE-ACT and lymphoma-specific STOP-CA evidence.
One key distinction: STOP-CA enrolled patients with lymphoma. Atorvastatin reduced LVEF-defined dysfunction, but clinical heart-failure reduction was not established. Statin decisions need the treatment, baseline risk and trial population in view.
Before ADT: check cardiovascular history, BP, lipids, glucose/HbA1c and ECG.
Then make a follow-up plan.
Other articles about Avirup Guha on OncoDaily.